Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.55 |
| ▸ | CSF1R | P07333 | 7/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.48 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 3/20 | 0.47 |
| ▸ | KIT | P10721 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30170765 | 1.00 | AR (0.55) | ARCSF1RNTRK1NTRK3NTRK2 | |
| SCHEMBL3490042 | 0.87 | MAOB (0.57) | ARMAOB | |
| SCHEMBL23949942 | 0.86 | MAOB (0.46) | ARMAOBMAOAAPP | |
| SCHEMBL8156292 | 0.86 | APP (0.53) | ARCSF1RMAOBMAOAAPP | |
| SCHEMBL23882866 | 0.86 | APP (0.53) | ARCSF1RMAOBMAOAAPP | |
| SCHEMBL7145572 | 0.82 | CA12 (0.61) | CSF1RNTRK1NTRK3NTRK2MAOB | |
| SCHEMBL2276512 | 0.82 | MAOB (0.68) | MAOBMAOAAPP | |
| SCHEMBL28838736 | 0.82 | MRGPRX4 (0.57) | ARMAOBMAOAAPP | |
| SCHEMBL7378373 | 0.82 | TUBB1 (0.48) | CSF1RMAOBMAOAAPP | |
| SCHEMBL23235862 | 0.82 | AR (0.55) | ARCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288595-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | GENZYME CORP (US) | 2025-09-18 | — | — | US | disclosed |
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | CULLGEN (SHANGHAI), INC. (CN) | 2025-09-09 | — | — | US | disclosed |
| US-12318392-B2 | Tropomyosin-related kinase (trk) inhibitors | GENZYME CORPORATION (US) | 2025-06-03 | — | — | US | disclosed |
| US-20240189322-A1 | TROPOMYOSIN-RELATED KINASE (trk) INHIBITORS | GENZYME CORPORATION | 2024-06-13 | — | — | US | disclosed |
| US-11878024-B2 | Tropomyosin-related kinase (Trk) inhibitors | GENZYME CORPORATION (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230080874-A1 | TROPOMYOSIN-RELATED KINASE (trk) INHIBITORS | GENZYME CORPORATION | 2023-03-16 | — | — | US | disclosed |
| CN-115697989-A | Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20150126503-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-05-07 | — | — | US | disclosed |
| US-8969568-B2 | Substituted naphthyridines and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2015-03-03 | — | — | US | disclosed |
| US-8969568-B2 | Substituted naphthyridines and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2015-03-03 | — | — | US | disclosed |
| US-8969568-B2 | Substituted naphthyridines and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2015-03-03 | — | — | US | disclosed |
| EP-2528915-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| WO-2011092128-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011092128-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | AR 690/4885CSF1R 4155/4885NTRK1 3/4885 |
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | NR4A3, NR0B1, NR4A1 | AR 805/4885CSF1R 2926/4885NTRK1 1233/4885 |
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | MUSK, ERBB2, NTRK1 | AR 690/4885CSF1R 4155/4885NTRK1 3/4885 |
| US-12318392-B2 | Tropomyosin-related kinase (trk) inhibitors | NTRK1, NGF, NTRK2 | AR 1488/4885CSF1R 4/4885NTRK1 1/4885 |
| US-20230080874-A1 | TROPOMYOSIN-RELATED KINASE (trk) INHIBITORS | NTRK1, NGF, NTRK2 | AR 1488/4885CSF1R 4/4885NTRK1 1/4885 |
| US-20240189322-A1 | TROPOMYOSIN-RELATED KINASE (trk) INHIBITORS | NTRK1, NGF, NTRK2 | AR 1488/4885CSF1R 4/4885NTRK1 1/4885 |
| US-11878024-B2 | Tropomyosin-related kinase (Trk) inhibitors | NTRK1, NGF, NTRK2 | AR 1488/4885CSF1R 4/4885NTRK1 1/4885 |
| US-20150126503-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | NR4A3, NR0B1, NR4A1 | AR 805/4885CSF1R 2926/4885NTRK1 1233/4885 |
| US-20250288595-A1 | TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | NTRK1, NGF, NTRK2 | AR 1488/4885CSF1R 4/4885NTRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.